ActivX Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- ActivX Biosciences's estimated annual revenue is currently $3.4M per year.
- ActivX Biosciences's estimated revenue per employee is $155,000
Employee Data
- ActivX Biosciences has 22 Employees.
- ActivX Biosciences grew their employee count by -21% last year.
ActivX Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | IT Manager | Reveal Email/Phone |
3 | Principal Research Scientist | Reveal Email/Phone |
4 | President and Chairman | Reveal Email/Phone |
5 | Research Associate II | Reveal Email/Phone |
ActivX Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is ActivX Biosciences?
ActivX is an emerging biopharmaceutical company that discovers and develops highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX uses its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with an initial focus on the areas of hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.
keywords:N/AN/A
Total Funding
22
Number of Employees
$3.4M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.2M | 22 | N/A | N/A |
#2 | $4.9M | 22 | -24% | N/A |
#3 | $4.3M | 23 | -12% | N/A |
#4 | $3.6M | 23 | 15% | N/A |
#5 | $3.6M | 23 | 0% | N/A |